 Rituximab may have good activity against MCL as a single agent, but it is typically given in combination with chemotherapies, which prolongs response duration.There are newer variations on monoclonal antibodies combined with radioactive molecules known as radioimmunotherapy (RIT).These include Zevalin and Bexxar.